NEW ISSUE - RADIATION RESEARCH - IS ACCESSIBLE ONLINE

https://meridian.allenpress.com/radiation-research/issue/196/5

 

 

 

NEW PROPOSED FY23 INITIATIVE FROM THE RNCP

  • RNCP Concept Clearance: Development of Radiation/Nuclear Medical Countermeasures (MCMs) and Biodosimetry Devices. BAA. This broad agency announcement serves as the Radiation and Nuclear Countermeasures Program’s only mechanism to solicit investigator-initiated mid-stage research directed to investigational new drug application or investigational use only-enabling efforts for the development of countermeasures to treat acute radiation syndrome (ARS), and/or delayed effects of acute radiation exposure (DEARE). This initiative will support the research and development of biodosimetry approaches to assess exposure level or approaches to mitigate/treat ARS and DEARE.

 

FUNDING OPPORTUNITIES

 

  • Notice of Special Interest (NOSI): Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (NOT-CA-22-001) NCI, NHLBI. The purpose of this Notice of Special Interest (NOSI) is to encourage collaborative and innovative approaches to mitigate cardiovascular dysfunction while optimizing cancer outcomes by understanding the mechanisms of cancer treatment-related cardiotoxicity and translating the findings to improve risk stratification, early detection, prevention, and management. Cardiovascular toxic anticancer treatments, including cytotoxic chemotherapy, targeted and immunomodulatory agents, and radiation, are used in single and combination treatment regimens across numerous cancer types.

 

  • Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed) (PAR-22-061) NCI. Application Receipt Date(s): January 07, 2025. The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter its effectiveness and thus those parameters should be rigorously addressed.

 

  • Notice of Special Interest (NOSI): Clinical Characterization and Intervention Strategies for Cancer Therapy Induced Adverse Sequelae (NOT-CA-22-005) NCI. The purpose of this Notice of Special Interest (NOSI) is to encourage P01 Research Program Project applications designed to address adverse sequelae of cancer therapies (including chemotherapy and radiation) that persist and become chronic comorbidities or develop as delayed posttreatment effects. The research focus of proposals should build upon mechanistic studies and include clinical phenotyping of adverse sequelae, the development and implementation of prevention or mitigation strategies, and validation of pre-clinical biomarkers in the clinical setting. Proposals should be focused on clinical and translational research supported by preliminary mechanistic research.
    National Cancer Institute

 

BARDA Funding Announcements

 

  • Amendment 29 to the BARDA BAA. Solicitation document attached to the email. Note Area of Interest #4 (page 24) and Area of Interest #7(page 37).

 

 

 

UPCOMING EVENTS

 

The goal of this meeting is to increase the awareness of the importance of mitochondria in disease initiation and progression, plus highlight the effects of unique environments on mitochondrial function and discuss what is needed to support the development of advanced diagnostics and sensors for bioenergetics that can monitor for disease onset and progression. AGENDA is HERE.

 

RECENT PUBLICATIONS

 

Article: “Ionizing irradiation-induced Fgr in senescent cells mediates fibrosis”

 

Dr. Joel Greenberger and colleagues report that upregulated Fgr in radiation-induced senescent cells mediates RIPF and is a potential therapeutic target for the prevention of this radiation late effect. [Cell Death Discov. 2021 Nov 12]

 

Amitava Mukherjee, Michael W Epperly, Donna Shields, Wen Hou, Renee Fisher, Diala Hamade, Hong Wang, M Saiful Huq, Riyue Bao, Tracy Tabib, Daisy Monier, Simon Watkins, Michael Calderon, Joel S Greenberger

 

Read more:

“Ionizing irradiation-induced Fgr in senescent cells mediates fibrosis”